Valion Bio presented its drug Entolimod, aimed at treating acute radiation syndrome (ARS), to senior U.S. Department of War and BARDA officials, highlighting interest in an oral formulation for easier field deployment. Entolimod offers a unique dual-tissue protective mechanism not found in current treatments, addressing both bone marrow and gastrointestinal damage from radiation. The drug has received FDA Fast Track and Orphan Drug designations and is advancing toward regulatory approval under the FDA's Animal Rule. Continued government engagement and funding underscore its potential as a key national radiological preparedness tool.
Privia Health Group, a national physician enablement company, announced its expansion into New Jersey through a partnership with Neurology Group of Bergen County (NGBC), a large neurology practice with 25 clinicians. NGBC will anchor the new Privia M...
AsymBio, a biologics CDMO, introduced its Conjugation Toolbox to support customized and scalable process development for next-generation bioconjugates like antibody-drug conjugates (ADCs). This platform offers flexible conjugation methods, including ...
Matlantis has introduced an AI agent integration using Anthropic's Claude Code to its atomistic simulation platform, allowing researchers to create and run simulations via natural language. This innovation removes the scripting barrier in computation...
JenaValve Technology, Inc. has appointed Edward Sarnowski as Chief Technology Officer to lead its research and development efforts. This move follows the recent FDA approval of JenaValve's Trilogy Transcatheter Heart Valve System, designed to treat s...
US stock futures increased following a tech-led rally, with the Nasdaq advancing while the Dow Jones fell in the previous session. The Federal Reserve is almost certain to keep interest rates unchanged in June, according to CME Group's FedWatch tool....
